Does metformin use lower gastric adenocarcinoma risk?

  • Zheng J & al.
  • Br J Cancer
  • 8 Oct 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Metformin use was not associated with decreased risk for gastric non-cardia or cardia adenocarcinoma during the follow-up for a median of 6 years.

Why this matters

  • At present, there is no clarity whether the use of metformin is associated with the risk for gastric adenocarcinoma.

Study design

  • This population-based study included a diabetes cohort of antidiabetes medication users (n=544,130) and a matched cohort of common-medication users (n=4,525,543).
  • Metformin non-users were frequency matched (10:1) with metformin users for sex and age.
  • The association between metformin use and risk for gastric non-cardia and cardia adenocarcinoma was assessed.
  • Funding: Swedish Cancer Society and others.

Key results

  • 6395 (0.1%) and 892 (0.1%) participants in diabetes and matched cohort of common-medication users developed gastric adenocarcinoma during a median follow-up of 5.8 years.
  • Metformin use was not associated with decreased risk for gastric adenocarcinoma (diabetes cohort: aHR, 1.08; 95% CI, 0.92-1.26; matched cohort: aHR, 1.38; 95% CI, 1.26-1.50).
  • The risk for gastric non-cardia adenocarcinoma was not significantly decreased in metformin users (diabetes cohort: aHR, 0.93; 95% CI, 0.78-1.12; matched cohort: aHR, 1.30; 95% CI, 1.18-1.42) compared with non-users.

Limitations

  • Lack of information on potential confounders, particularly obesity.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit